^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Hyaluronidase stimulant

    Related drugs:
    Apply
    Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (RTB) (NCT03284268)
    Phase N/A
    Fundació Sant Joan de Déu
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    09/06/2017
    Primary completion :
    06/15/2024
    Completion :
    07/01/2024
    RB1
    |
    RB1 mutation
    |
    VCN-01
    Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma (NCT03799744)
    Phase 1
    Institut Català d'Oncologia
    Active, not recruiting
    Last update posted :
    03/28/2022
    Initiation :
    03/20/2019
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    IL6 • IL10
    |
    Imfinzi (durvalumab) • VCN-01
    Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer (NCT04058964)
    Phase 2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    03/13/2020
    Initiation :
    02/01/2020
    Primary completion :
    10/31/2022
    Completion :
    10/31/2022
    PD-L1
    |
    Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)
    A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors (NCT02563548)
    Phase 1b
    Halozyme Therapeutics
    Completed
    Last update posted :
    02/07/2020
    Initiation :
    10/22/2015
    Primary completion :
    03/26/2019
    Completion :
    03/26/2019
    PD-L1 • ALK • PD-1
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)
    Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer (NCT01453153)
    Phase 1b/2
    Halozyme Therapeutics
    Completed
    Last update posted :
    11/30/2018
    Initiation :
    09/01/2011
    Primary completion :
    02/01/2014
    Completion :
    05/01/2015
    CA 19-9
    |
    gemcitabine • pegvorhyaluronidase alfa (PEGPH20)